GM Advisory Group LLC Buys 397 Shares of Eli Lilly and Company (NYSE:LLY)

GM Advisory Group LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,386 shares of the company’s stock after buying an additional 397 shares during the quarter. GM Advisory Group LLC’s holdings in Eli Lilly and Company were worth $8,790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. North Forty Two & Co. bought a new position in Eli Lilly and Company in the 4th quarter valued at $505,000. VSM Wealth Advisory LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at $1,357,000. Enhancing Capital LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at $6,408,000. Halter Ferguson Financial Inc. raised its position in Eli Lilly and Company by 16.6% in the 4th quarter. Halter Ferguson Financial Inc. now owns 6,801 shares of the company’s stock valued at $5,250,000 after purchasing an additional 968 shares during the last quarter. Finally, Generali Asset Management SPA SGR bought a new position in Eli Lilly and Company in the 4th quarter valued at $54,907,000. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research report on Friday, January 17th. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research report on Thursday, March 6th. Truist Financial lifted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Citigroup lowered their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America reissued a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,009.72.

Eli Lilly and Company Stock Down 0.4 %

Shares of Eli Lilly and Company stock opened at $821.67 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The business has a fifty day simple moving average of $833.02 and a 200 day simple moving average of $840.71. The stock has a market cap of $779.08 billion, a PE ratio of 70.17, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a stock repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.